Report LibraryAll Reports
Datamonitor Healthcare Oncology Disease Analysis: Gastric Cancer
September 11, 2023
HER2, PD-1, and receptor tyrosine kinases (RTKs) are the most common molecular targets for both branded and pipeline drugs. However, the treatment landscape remains dominated by non-targeted chemotherapies, with most targeted agents confined to one or two treatment settings, where they are typically administered alongside chemotherapy.
No targeted therapies exist for locoregional disease, although various PD-1 inhibitors are under investigation.
This Datamonitor Healthcare report contains a Disease Analysis module.
|Indications Covered:||Gastric Cancer|